RecruitingVestibular Migraine
Acute Treatment of Vestibular Migraine by Rimegepant
Eligible age
18–60 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.
Sponsor: Wensheng Qu
You may qualify if…
- ✓ 1. Age 18-60 years, male or female.
- ✓ 2. Diagnosis of vestibular migraine according to the Bárány Society criteria.
- ✓ 3. ≥4 episodes of characteristic vestibular symptoms in the past year, each of moderate to severe intensity and lasting \>2 hours (without intervention).
- ✓ 4. Signed informed consent obtained from the participant.
You may not qualify if…
- ✕ 1. Presence of other disorders causing acute vestibular symptoms (e.g., Ménière's disease, otitis media).
- ✕ 2. Coexisting non-vertiginous dizziness (e.g., dizziness due to panic disorder), unless the patient can clearly distinguish these episodes from vestibular-migraine attacks.
- ✕ 3. Severe hepatic dysfunction (ALT and/or AST \>3× upper limit of normal) or renal impairment (creatinine clearance \<30 mL/min).
- ✕ 4. Severe cardiovascular or cerebrovascular disease.
- ✕ 5. Alcohol abuse or substance abuse.
- ✕ 6. Known pregnancy or lactation, or a positive pregnancy test prior to randomization.
- ✕ 7. Contraindication or hypersensitivity to any medications used in the study.
- ✕ 8. Initiation or dose adjustment of any preventive migraine therapy within 3 months prior to study drug administration.
Source: ClinicalTrials.gov · NCT07871097 · last updated 2026-10-13